A phase I open-label, single-arm, dose escalation study of E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumours
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2009
At a glance
- Drugs E 7107 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Apr 2009 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
- 20 Jun 2007 New trial record.